Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study.
about
Clinical implications of compounds designed to inhibit ECM-modifying metalloproteinases.Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis.
P2860
Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Inhibition of Breast Cancer Me ...... ical Proof-of-Principle Study.
@en
type
label
Inhibition of Breast Cancer Me ...... ical Proof-of-Principle Study.
@en
prefLabel
Inhibition of Breast Cancer Me ...... ical Proof-of-Principle Study.
@en
P2093
P2860
P50
P1476
Inhibition of Breast Cancer Me ...... nical Proof-of-Principle Study
@en
P2093
Arthur Winer
Beth Harrison
Dariush Moussai
Jennifer Zeng
Maxwell Janosky
Nina Schatz-Siemers
Pinar Siyah
P2860
P304
P356
10.1158/1535-7163.MCT-16-0194
P577
2016-07-27T00:00:00Z